CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
游离 DNA 动态浓度及其他变量是弥漫大 B 细胞淋巴瘤患者 CAR-T 细胞治疗后早期进展的预测因素
英文原题：Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma.
查看英文原题
Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们提出一种新型生物标志物，可识别嵌合抗原受体（CAR）T细胞治疗后早期进展风险较高的患者。使用单采前（PA）和淋巴细胞清除前（PL）样本计算无细胞DNA（cfDNA），可监测肿瘤动态变化（ΔcfDNA）。本研究评估了58例复发/难治性弥漫大B细胞淋巴瘤（DLBCL）患者的cfDNA、其他生物标志物和临床变量。输注后1个月疾病进展与以下因素高度相关：cfDNA>11 ng/mL血浆（P=0.003）、PL时C反应蛋白（CRP）>1.06 mg/dL（P=0.004）、PL时乳酸脱氢酶（LDH）>304（P=0.006）、PL时疾病状态为进展性疾病（P=0.035）以及男性（P=0.016）。校正cfDNA、PL时CRP和LDH、PL时疾病状态及性别后，cfDNA仍与CAR-T 细胞输注后1个月进展相关。
展开英文摘要原文
We propose a novel biomarker that can identify patients at high risk of early progression after chimeric antigen receptor (CAR) T cell therapy. Calculation of cell-free DNA (cfDNA) with a pre-apheresis (PA) and pre-lymphodepletion (PL) sample allows monitoring of tumor dynamics ( cfDNA). In the present study, cfDNA and other biomarkers and clinical variables were evaluated in 58 patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).
cfDNA (>11 ng/mL plasma; P =. 003), C-reactive protein (CRP) PL (>1. 06 mg/dL; P = . 004), lactate dehydrogenase (LDH) PL (>304; P = . 006), disease status PL (progressive disease; P = . 035) and sex (male; P = . 016) were highly correlated with 1 month progression. After adjusting for cfDNA, CRP PL, and LDH PL, disease status PL, and sex, cfDNA remained associated with 1-month progression after CAR T cell infusion.
论文信息
- 作者
- Bastos-Oreiro M、Sanz-Villanueva L、Muñiz P、Bailén R、Chicano M、Oarbeskoa G、Gómez I、Gutiérrez A
- 第一作者单位
- Department of Haematology, Gregorio Marañón General University Hospital, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain.Spain
- 通讯作者单位
- Department of Haematology, Gregorio Marañón General University Hospital, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: cmlaperchehgugm@gmail.com.Spain
- 文献类型
- 非美国政府资助研究
- 期刊
- Transplantation and cellular therapy2023 Jul
- 原文标识
- PubMed 36921917 · DOI 10.1016/j.jtct.2023.03.009